Overview

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Status:
Enrolling by invitation
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, fixed dose, 26 week study of patients with MDD. Eligible patients from the lead-in studies will enter the Open-label Safety Study at the Screening/Baseline Visit (Visit 1/Day 1), at which point patient eligibility will be assessed and informed consent obtained.
Phase:
Phase 3
Details
Lead Sponsor:
Intra-Cellular Therapies, Inc.